Navigation Links
New Data Supports ConvaTec Negative Pressure Wound Therapy
Date:8/17/2009

SKILLMAN, N.J., Aug. 17 /PRNewswire/ -- ConvaTec, a world-leading developer and marketer of innovative medical technologies for community and hospital care, announced today the publication of new data demonstrating positive clinical results achieved with the Engenex((R)) Advanced Negative Pressure Wound Therapy (NPWT) system.

The Engenex((R)) NPWT System, utilizing low pressure (75 mm Hg) and EasyRelease(TM) dressings incorporating Bio-Dome(TM) Interface Technology, is designed to safely and effectively promote the healing of difficult wounds.

The case series study, published in the June issue of the journal Ostomy Wound Management, evaluated use of the next generation NPWT system in the management of complex surgical and traumatic wounds. Following the application of the NPWT system in a protocol of care, all three cases showed a marked progression toward wound healing, with reduced wound volume and development of healthy granulated tissue. Clinicians also observed that the dressing - developed specifically for use with the Engenex((R) )NPWT system - was well tolerated, with no tissue growth into the dressing, "little to no" disturbance of the granulation bed during dressing changes, and "little to no" bleeding or trauma on removal of the dressing.

"As our experience and these cases suggest, we believe that the Engenex NPWT System, with its low pressure profile and unique, non-adherent dressings, may represent an advance in this technology, possibly benefiting wound and patient outcomes," said author Cheryl Nease, PT, Memorial Health Center in Savannah, GA.

In December 2008, ConvaTec signed a long-term global exclusive license agreement with Boehringer Technologies to market and distribute the Engenex((R)) NPWT System incorporating Bio-Dome(TM) Interface Technology. The Engenex((R)) NPWT System is an innovative technology and engineering solution that utilizes the application of negative pressure to a wound to promote healing by creating controlled tissue strain and removing excess fluid, including wound exudate. Every aspect of the System, from the wound interface to the user interface, has been designed to attain optimal clinical outcomes as well as a simplified application and monitoring system for patient care.

"This publication is just the beginning in the development of our clinical evidence base in support of this advanced NPWT technology," said Marcus Schabacker, Chief Scientific Officer, ConvaTec. "As the researcher noted, the acceptable levels of observed pain, exudate management, minimal bleeding and wound bed disruption are important factors for clinicians managing complex wounds and for the patients they care for - and validates the excellent response we have been receiving from our initial customers."

About ConvaTec

ConvaTec is a leading developer and marketer of innovative medical technologies that have helped improve the lives of millions of people worldwide. With four key business divisions - Ostomy Care, Wound Therapeutics, Continence and Critical Care and Infusion Devices - ConvaTec products support health care professionals from the hospital to the community health setting. From its headquarters in Skillman, New Jersey, the company oversees more than 8,000 employees in over 90 countries serving consumers and their health care professionals on six continents. For more information, please visit www.convatec.com.

Engenex is a registered trademark, and EasyRelease and Bio-Dome are trademarks of Boehringer Technologies L.P.

Our world is what we make of it is a trademark of ConvaTec Inc.

(C) 2009 ConvaTec Inc.

AP-007938-US

(1) Nease C. Using low pressure, negative pressure wound therapy for wound preparation and the management of split-thickness skin grafts in three patients with complex wounds. Ostomy Wound Management 2009;55(6)32-42.

    Contacts

    Punnie Donohue
    ConvaTec
    908-904-2151
    punnie.donohue@convatec.com

    Courtney Judd
    Weber Shandwick
    212-445-8365
    cjudd@webershandwick.com


'/>"/>
SOURCE ConvaTec
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. New Study Supports Efficacy of Vagus Nerve Stimulation for Treatment-Resistant Depression
2. Cell Therapeutics, Inc. (CTI) Supports Panel Discussion on Women and Lung Cancer on Capitol Hill
3. Survival Data in FDA Approval for ERBITUX(R) (Cetuximab) Supports use as a Single Agent in Patients with Advanced Colorectal Cancer
4. Cost-Effectiveness Study Supports Use of EUFLEXXA(TM) by Rheumatologists for Pain Relief in Patients with Knee Osteoarthritis
5. New Data from the Framingham Heart Study Supports PAT Technology to Diagnose Early Cardiovascular Disease
6. Powerful New Efficacy Data in Moderate and Severe Hypertensive Patients Supports FDA Approval of AVALIDE(R) (Irbesartan-Hydrochlorothiazide) as the First Combination Therapy for Initial Use in Patients Likely to Need Multiple Drugs to Achieve Their Blood
7. Interim Safety Analysis Supports Continuation of Allos Therapeutics Pivotal Phase 2 PROPEL Trial of PDX in Patients with Peripheral T-cell Lymphoma
8. Interim Analysis Supports Continuation of Cell Genesys VITAL-1 Phase 3 Clinical Trial of GVAX Immunotherapy for Prostate Cancer
9. FDA Advisory Committee Supports Efficacy and Safety of Zyprexa(R) Long-Acting Injection (LAI) for Schizophrenia Treatment
10. HUYA Bioscience Intl Announces Clinical Trial Milestones in China for Promising New Anti-Arrhythmic Compound; Data Supports Desirable Safety Profile
11. New Clinical Data Further Supports Chromium Picolinates Role in Enhancing Brain Activity in Older Adults
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2016)... , Feb. 8, 2016  The University of ... announced today that, as part of the development ... of the first hospitals in the U.S. to start ... Muraszko , M.D., U-M,s chair of neurosurgery. ... neurosurgery. --> The BrightMatter technology from ...
(Date:2/8/2016)... CITY, Calif., Feb. 8, 2016  Aoxing Pharmaceutical Company, Inc. (NYSE ... fiscal year 2016, ended December 31, 2015, the Company achieved ... recorded in the same quarter in fiscal 2015. ... in Q2 of fiscal year 2016 was $2,068,635, or $.03 ... or $.01 per share, in the Q2 of fiscal year ...
(Date:2/8/2016)... Feb. 8, 2016 ... of the "Label-Free Detection Market by ... 2020" report to their offering. ... addition of the "Label-Free Detection Market ... to 2020" report to their offering. ...
Breaking Medicine Technology:
(Date:2/8/2016)... ... February 08, 2016 , ... Tingley Rubber ... Canada to provide its range of unique and advantaged protective solutions to ... that will provide bilingual customer service and marketing support. A new distribution center ...
(Date:2/8/2016)... (PRWEB) , ... February 08, ... ... and security executive networking and relationship-marketing firm, announced today that nominations will ... Information Security Executive® (ISE®) West Awards. , Awards include the Information ...
(Date:2/8/2016)... ... February 08, 2016 , ... GrassrootsHealth published data from its ... 2 diabetes in the GrassrootsHealth cohort with substantially higher vitamin D levels than ... public health,” states Carole Baggerly, Director of GrassrootsHealth, “the safety and benefits ...
(Date:2/8/2016)... ... February 08, 2016 , ... The schedule is ... this country. The AutismOne 2016 Conference, which is being held May 25-29 at the ... hear elsewhere about helpful interventions and causes of chronic illness in children. , Very ...
(Date:2/7/2016)... ... February 07, 2016 , ... Dr. Todd ... to his medical and surgical expertise. Technically known as deoxycholic acid or previously ... as a non-surgical alternative for reduction of fat below the chin (aka the ...
Breaking Medicine News(10 mins):